Calcium Pyrophosphate Deposition Disease (CPPD) Management and Pathophysiology

Pathophysiology and Disease Mechanism

CPPD develops when elevated inorganic pyrophosphate levels in cartilage lead to CPP crystal formation and deposition, with no current treatment to prevent CPP crystal formation or enhance their dissolution, fundamentally limiting management to symptomatic control rather than disease modification, according to the European League Against Rheumatism 1, 2
Interleukin-1 (IL-1) plays a central role in the inflammatory response in CPPD, as stated by the American College of Rheumatology 1
Magnesium deficiency promotes crystal formation, as magnesium normally solubilizes CPP crystals and inhibits their nucleation, as reported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases 1

Radiographic calcium deposits in cartilage without symptoms are common in asymptomatic CPPD (chondrocalcinosis), particularly in elderly patients, with a prevalence increasing dramatically with age, according to the American Geriatrics Society 3
Primary hyperparathyroidism is associated with a 3-fold increased risk of CPPD (OR=3.03), as reported by the Endocrine Society 4
Hypomagnesemia is a metabolic association of CPPD, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 4, 1

Ultrasound and CT can detect crystal deposits in CPPD, with CT being particularly useful for axial joints, such as crowned dens syndrome, as reported by the Radiological Society of North America 3

The primary goal of CPPD management is symptomatic control of inflammation and prevention of acute attacks, as no disease-modifying treatments exist, according to the American College of Rheumatology 2, 5
Hydroxychloroquine showed clinical response (NNT=2) in chronic inflammatory arthritis, as reported by the European League Against Rheumatism 4
Low-dose weekly methotrexate may be valuable for severe refractory disease, as stated by the American College of Rheumatology 4